AbbVie (ABBV) Tops Q4 EPS by 3c, Confirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AbbVie (ABBV) PT Trimmed at Jefferies But Sees Excellent Entry Point
February 3, 2015 8:41 AM ESTJefferies analyst Jeffrey Holford reiterated a Buy rating on Abbvie (NYSE: ABBV) following Q4 results but lowered his price target to $80.00 (from $82.00). The firm said recent weakness creates an excellent entry point.
Holford commented, "We view ABBV's 2015 HCV guidance as conservative, which is... More
